Bile duct neoplasm

Summary

Bile duct neoplasm (MONDO:0021662) is a cancer and 19 clinical trials. Top therapeutic interventions include tivozanib, floxuridine, and sorafenib. A subtype of bile duct disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 19

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bile duct neoplasm
Mondo ID	MONDO:0021662
MeSH	D001650
NCIT	C2898
UMLS	C0005396
MedGen	14114
Anatomy (UBERON)	UBERON:0002394
Is cancer (heuristic)	yes

Also known as: bile duct neoplasm · bile duct neoplasm (disease) · bile duct tumor · bile duct tumour · intrahepatic and extrahepatic bile duct neoplasm · intrahepatic and extrahepatic bile duct tumor · intrahepatic and extrahepatic bile duct tumour · neoplasm of bile duct · tumor of bile duct · tumour of bile duct

Disease family

This is a subtype of bile duct disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › bile duct neoplasm

Related subtypes (6): perforation of bile duct, cholestasis, common bile duct disorder, non-neoplastic bile duct disorder, bile duct cyst, fibrosis of bile duct

Subtypes (4): bile duct cancer, bile duct papillary neoplasm, bile duct adenoma, extrahepatic bile duct neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Capecitabine, Carboplatin, Ceralasertib, Cisplatin, Durvalumab, Fluorouracil, Gemcitabine, Olaparib, Oxaliplatin, Tremelimumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 19.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE1/PHASE2	2
PHASE2	2
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01969110	PHASE4	UNKNOWN	Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
NCT01622803	PHASE3	WITHDRAWN	Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction
NCT04645160	PHASE1/PHASE2	RECRUITING	Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT05286814	PHASE2	RECRUITING	PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT00634751	PHASE1/PHASE2	COMPLETED	CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
NCT01845337	PHASE2	COMPLETED	Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
NCT05172310	PHASE1	RECRUITING	PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
NCT00582647	Not specified	ACTIVE_NOT_RECRUITING	Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
NCT07558304	Not specified	NOT_YET_RECRUITING	Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial)
NCT00915863	Not specified	UNKNOWN	Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy
NCT01232101	Not specified	COMPLETED	Covered or Uncovered Bile Duct Stents
NCT03838913	Not specified	UNKNOWN	Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB)
NCT03951324	Not specified	UNKNOWN	Volumetric Laser Endomicroscopy’s (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
NCT04276090	Not specified	TERMINATED	Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
NCT04847167	Not specified	COMPLETED	Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy
NCT05320328	Not specified	UNKNOWN	RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION
NCT05374122	Not specified	UNKNOWN	AI Guidance for Biopsy in Suspected Cholangiocarcinoma
NCT05600803	Not specified	UNKNOWN	Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
NCT06115655	Not specified	UNKNOWN	A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TIVOZANIB	4	2
FLOXURIDINE	4	1
SORAFENIB	4	1